These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 20692140)

  • 1. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
    Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
    Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
    Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
    Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD.
    Berton DC; Reis M; Siqueira AC; Barroco AC; Takara LS; Bravo DM; Andreoni S; Neder JA
    Respir Med; 2010 Sep; 104(9):1288-96. PubMed ID: 20580216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
    Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of formoterol on exercise tolerance in severely disabled patients with COPD.
    Neder JA; Fuld JP; Overend T; Thirlwell J; Carter R; Stevenson R; Ward SA
    Respir Med; 2007 Oct; 101(10):2056-64. PubMed ID: 17658249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.
    Ställberg B; Selroos O; Vogelmeier C; Andersson E; Ekström T; Larsson K
    Respir Res; 2009 Feb; 10(1):11. PubMed ID: 19228428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
    Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.
    Celli BR; Tashkin DP; Rennard SI; McElhattan J; Martin UJ
    Respir Med; 2011 Aug; 105(8):1176-88. PubMed ID: 21531124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD.
    Williamson PA; Short PM; Clearie KL; Vaidyanathan S; Fardon TC; Howaniec LJ; Lipworth BJ
    Chest; 2010 Sep; 138(3):595-604. PubMed ID: 20418370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
    Szafranski W; Cukier A; Ramirez A; Menga G; Sansores R; Nahabedian S; Peterson S; Olsson H
    Eur Respir J; 2003 Jan; 21(1):74-81. PubMed ID: 12570112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial.
    Watz H; Kirsten AM; Ludwig-Sengpiel A; Krüll M; Mroz RM; Georges G; Varoli G; Charretier R; Cortellini M; Vele A; Galkin D
    Respir Res; 2024 Oct; 25(1):378. PubMed ID: 39420338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.